Key result
Trans-2S,5S neolignan enantiomers exhibit ~10-200 times greater in vitro PAF receptor antagonism than corresponding isomers.
Why the study?
The biological justification for concomitant inhibition of both PAF receptor and 5-lipoxygenase in inflammation is well recognized, motivating development of novel PAF receptor antagonists.
Lignan analogs demonstrate potent, stereospecific antagonism of the PAF receptor, with potential for dual inhibition of PAF and 5-lipoxygenase in inflammation.
Answers are grounded in this paper and cite their sources.
Trans-2S,5S neolignan enantiomers may guide stereoselective PAF antagonist design; leaves open therapeutic potential pending in vivo studies.
Various derivatives and isosteres of neolignans of the 2,5-diaryl tetrahydrofuran type have been synthesized as antagonists of platelet-activating factor (PAF). A detailed analysis of their structure-activity relationship (SAR) has revealed a clear preference for an asymmetrical molecular configuration with a high degree of stereo and chiral specificity associated with greater potency. The trans-2S,5S enantiomers are generally 10-200 times more potent in vitro than their corresponding cis or trans-2R,5R isomers. A similar stereochemical preference is indicated by the recently reported PAF antagonist MK-287 which has undergone clinical evaluation. An azido derivative L-662,025 has been characterized as a photolabile irreversible antagonist of PAF for the investigation of solubilized and partially purified PAF binding proteins from cell membranes. The biological justification for concomitant inhibition of both PAF receptor and 5-lipoxygenase in inflammation is well recognized. The feasibility of developing such dual-functional agents has been demonstrated by a group of dithiolane analogs of neolignans and several derivatives of futoenone.
No takes yet. Share an insight, caveat, or question.
T. Y. Shen (1991) studied this question. Lignan analogs (2,5-diaryl tetrahydrofuran type neolignans) was evaluated on In vitro potency as platelet-activating factor (PAF) antagonists. Trans-2S,5S enantiomers of 2,5-diaryl tetrahydrofuran neolignans were 10-200 times more potent in vitro as PAF receptor antagonists than their corresponding cis or trans-2R,5R isomers.
Synapse has enriched 10 related papers. Consider them for comparative context: